Asthma season is in full swing and AstraZeneca is raising awareness about its severe asthma treatment, Fasenra, as part of its ongoing Stepping Back Out campaign. The latest installment of the ...
AstraZeneca experienced some setbacks last year on its quest to expand its asthma drug Fasenra to treat other conditions like rhinosinusitis and eosinophilic esophagitis. However, the British pharma ...
A Phase II investigator-led trial investigating AstraZeneca’s Fasenra (benralizumab) treating eosinophilic exacerbations of asthma and chronic obstructive pulmonary disease (COPD) has demonstrated a ...
An ad within an ad is the theme of AstraZeneca’s first DTC campaign for Fasenra. In the recently released TV commercial, scientists on TV talk about eosinophilic asthma while potential patients watch ...
AstraZeneca's Fasenra (bevacizumab) is set to challenge GSK’s Nucala (mepolizumab) in eosinophilic granulomatosis with polyangiitis (EGPA) as the US Food and Drug Administration (FDA) approved the ...
The FDA has expanded the approval of Fasenra (benralizumab; AstraZeneca) to include self-administration with the Fasenra Pen, a prefilled, single-use autoinjector. The Food and Drug Administration ...
FASENRA is now the only respiratory biologic that offers the choice of administration at home or in a doctor’s office with eight-week maintenance dosing WILMINGTON, Del.--(BUSINESS WIRE)-- AstraZeneca ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback